Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs
Auris Medical Holding Ltd (NASDAQ:EARS) has acquired privately-held Trasir Therapeutics Inc, focused on extrahepatic oligonucleotide delivery. The purchase price comprises 0.77…